First pill of its kind tested to fight Tough-to-Treat lymphoma
NCT ID NCT06393738
Summary
This is the first study to test a new oral drug called ARV-393 in people. It aims to see if the drug is safe and if it can help control advanced non-Hodgkin's lymphoma that has come back or stopped responding to other treatments. The drug is designed to break down a specific protein in cancer cells, which may slow or stop tumor growth. The study will enroll adults who have already tried at least two other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY (R/R) MATURE B CELL NON HODGKIN LYMPHOMA (NHL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Trial Site
RECRUITINGNew Haven, Connecticut, 06510, United States
-
Clinical Trial Site
RECRUITINGDetroit, Michigan, 48201, United States
-
Clinical Trial Site
RECRUITINGNew Brunswick, New Jersey, 10065, United States
-
Clinical Trial Site
RECRUITINGNew York, New York, 10016, United States
-
Clinical Trial Site
RECRUITINGNew York, New York, 10021, United States
-
Clinical Trial Site
RECRUITINGCleveland, Ohio, 44122, United States
-
Clinical Trial Site
RECRUITINGNashville, Tennessee, 37203, United States
-
Clinical Trial Site
RECRUITINGHouston, Texas, 77030, United States
-
Clinical Trial Site
RECRUITINGToronto, Ontario, M5G 1Z5, Canada
-
Clinical Trial Site
RECRUITINGMontreal, Quebec, H3T 1E2, Canada
-
Clinical Trial Site
RECRUITINGCopenhagen, 2100, Denmark
-
Clinical Trial Site
RECRUITINGOdense C, 5000, Denmark
-
Clinical Trial Site
RECRUITINGEl Palmar, Murcia, 30120, Spain
-
Clinical Trial Site
RECRUITINGPamplona, Navarre, 31008, Spain
-
Clinical Trial Site
RECRUITINGBarcelona, 8908, Spain
-
Clinical Trial Site
RECRUITINGMadrid, 28050, Spain
-
Clinical Trial Site
RECRUITINGSalamanca, 37007, Spain
Conditions
Explore the condition pages connected to this study.